![](https://www.pymnts.com/wp-content/uploads/2020/04/shutterstock_1076076800-e1573824358493-1.jpg)
With India facing a major health emergency due to the novel Coronavirus pandemic, the Competition Commission of India (CCI) announced that antitrust laws allow rivals in various critical sectors healthcare products and other essential commodities and services can engage in greater coordination without the fear of any adverse action.
“The Act has in-built safeguards to protect businesses from sanctions for certain coordinated conduct, provided such arrangements, as mentioned above, result in increasing efficiencies. These provisions will inform the decisions of the Commission,” the antitrust watchdog stated in an advisory to businesses on Sunday, April 19.
However, the CCI added that only such conduct of businesses which is necessary and proportionate to address concerns arising from COVID-19 will be considered, and companies should not take advantage of the pandemic to contravene any of the provisions of competition laws.
The CCI cited essential medical products like ventilators, face masks, gloves, vaccines, services like testing and logistics, and essential commodities as examples where it would use a more liberal approach to enforcing antitrust laws.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan